MCID: JVN004
MIFTS: 69

Juvenile Myelomonocytic Leukemia

Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Juvenile Myelomonocytic Leukemia

MalaCards integrated aliases for Juvenile Myelomonocytic Leukemia:

Name: Juvenile Myelomonocytic Leukemia 54 38 12 50 56 29 52 14 69
Leukemia, Juvenile Myelomonocytic 54 50 71 13
Jmml 50 56 71
Leukemia, Juvenile Myelomonocytic, Somatic 54
Juvenile Chronic Myelomonocytic Leukemia 56
Juvenile Chronic Myelogenous Leukemia 71
Leukemia, Myelomonocytic, Juvenile 42

Characteristics:

Orphanet epidemiological data:

56
juvenile myelomonocytic leukemia
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Childhood,Infancy;

OMIM:

54
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
one family has been reported with germline cbl mutation (last curated may 2016)


HPO:

32
juvenile myelomonocytic leukemia:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 54 607785
Disease Ontology 12 DOID:0050458
ICD10 33 C93.3 C93.30
MeSH 42 D054429
NCIt 47 C9233
Orphanet 56 ORPHA86834
MESH via Orphanet 43 D054429
UMLS via Orphanet 70 C0349639
ICD10 via Orphanet 34 C93.3
UMLS 69 C0349639

Summaries for Juvenile Myelomonocytic Leukemia

OMIM : 54
Juvenile myelomonocytic leukemia is an aggressive pediatric myelodysplastic syndrome (MDS)/myeloproliferative disorder (MPD) characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny (Loh et al., 2009). JMML constitutes approximately 30% of childhood cases of myelodysplastic syndrome and 2% of leukemia (Hasle et al., 1999). Although JMML is a progressive and often rapidly fatal disease without hematopoietic stem cell transplantation (HSCT), some patients have been shown to have a prolonged and stable clinical course without HSCT (Niemeyer et al., 1997). Chronic myelomonocytic leukemia (CMML) is a similar disorder with later onset. Both JMML and CMML have a high frequency of mutations affecting the RAS signaling pathway and show hypersensitivity to stimulation with GM-CSF, which causes STAT5 (601511) hyperphosphorylation (Loh et al., 2009). (607785)

MalaCards based summary : Juvenile Myelomonocytic Leukemia, also known as leukemia, juvenile myelomonocytic, is related to noonan syndrome 7 and noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia, and has symptoms including exanthema, fatigue and fever. An important gene associated with Juvenile Myelomonocytic Leukemia is PTPN11 (Protein Tyrosine Phosphatase, Non-Receptor Type 11), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Busulfan and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid, and related phenotypes are Decreased viability and cellular

NIH Rare Diseases : 50 this condition doesn't have a summary yet. please see our page(s) on myelodysplastic/myeloproliferative disease.

UniProtKB/Swiss-Prot : 71 Leukemia, juvenile myelomonocytic: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.

Wikipedia : 72 Juvenile myelomonocytic leukemia (JMML) is a serious chronic leukemia (cancer of the blood) that affects... more...

Related Diseases for Juvenile Myelomonocytic Leukemia

Diseases in the Chronic Myelomonocytic Leukemia family:

Juvenile Myelomonocytic Leukemia

Diseases related to Juvenile Myelomonocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
id Related Disease Score Top Affiliating Genes
1 noonan syndrome 7 31.8 BRAF KRAS PTPN11 RAF1 SOS1 SPRED1
2 noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia 12.5
3 juvenile myelomonocytic leukemia, somatic arhgap26-related 12.1
4 juvenile myelomonocytic leukemia, somatic cbl-related 12.1
5 juvenile myelomonocytic leukemia, somatic nf1-related 12.1
6 juvenile myelomonocytic leukemia, somatic ptpn11-related 12.1
7 noonan syndrome 9 11.1
8 noonan syndrome 10 11.1
9 noonan syndrome 6 11.1
10 noonan syndrome 8 11.1
11 noonan syndrome 4 11.1
12 noonan syndrome 5 11.1
13 noonan syndrome 3 11.1
14 myelodysplastic myeloproliferative cancer 11.1
15 noonan syndrome 1 11.1
16 leukemia 10.9
17 raf1-related noonan syndrome 10.8 BRAF NRAS PTPN11
18 internal hordeolum 10.8 PTPN11 SOS1
19 schimmelpenning-feuerstein-mims syndrome, somatic mosaic 10.7 KRAS NRAS
20 ocular albinism, x-linked 10.7 BRAF PTPN11 RAF1
21 coloboma of inferior eyelid 10.7 BRAF KRAS
22 growth restriction, severe, with distinctive facies 10.7 KRAS PTPN11 SOS1
23 watson syndrome 10.7 NF1 PTPN11
24 primary cutaneous peripheral t-cell lymphoma not otherwise specified 10.7 SETBP1 TET2
25 autosomal dominant deafness-onychodystrophy syndrome 10.7 NF1 PTPN11 SPRED1
26 pulmonary valve agenesis-tetralogy of fallot-absence of ductus arteriosus syndrome 10.7 FLT3 RUNX1
27 non-distal trisomy 10q 10.7 BRAF KRAS NRAS
28 progressive multifocal leukoencephalopathy 10.6 PTPN11 SOS1 SPRED1
29 interstitial nephritis, karyomegalic 10.6 NF1 PTPN11 SPRED1
30 cervical serous adenocarcinoma 10.6 PTPN11 SOS1 SPRED1
31 laryngeal neuroendocrine tumor 10.5 BRAF KRAS
32 brachydactyly-distal symphalangism syndrome 10.5 CSF2 FLT3
33 radioulnar synostosis 10.5 BRAF KRAS NF1 PTPN11 RAF1
34 diencephalic astrocytomas 10.4 BRAF KRAS NF1 PTPN11 RAF1
35 sexual masochism 10.4 KRAS RAF1
36 dyserythropoietic anemia and thrombocytopenia 10.4 CBL FLT3 KRAS NRAS RUNX1
37 skin epithelioid hemangioma 10.3 BRAF NF1 PTPN11 RAF1 SPRED1
38 hemolytic anemia 10.3 CSF2 FLT3 PTPN11 RUNX1
39 chronic venous leg ulcers 10.3 FLT3 RUNX1 SETBP1 TET2
40 hematopoietic stem cell transplantation 10.3
41 hypocalciuric hypercalcemia, type i 10.3 CSF2 FLT3 NRAS TET2
42 myelodysplastic syndrome 10.3
43 nelson syndrome 10.3 CSF2 FLT3 NF1 PTPN11 RUNX1
44 peroxisome biogenesis disorder 7a 10.2 CSF2 FLT3 NRAS RUNX1 SETBP1
45 pineal gland astrocytoma 10.2 BRAF NF1
46 nephrolithiasis 10.2 CSF2 NF1 NRAS PTPN11 SETBP1 TET2
47 neurofibromatosis, type 1 10.2
48 lymphoblastic leukemia 10.1
49 bernard-soulier syndrome, type c 10.1 BRAF CSF2 FLT3 KRAS RAF1
50 cheek mucosa cancer 10.1 CSF2 FLT3 PTPN11 RUNX1 TET2

Graphical network of the top 20 diseases related to Juvenile Myelomonocytic Leukemia:



Diseases related to Juvenile Myelomonocytic Leukemia

Symptoms & Phenotypes for Juvenile Myelomonocytic Leukemia

Symptoms via clinical synopsis from OMIM:

54

Hematology:
juvenile myelomonocytic leukemia


Clinical features from OMIM:

607785

Human phenotypes related to Juvenile Myelomonocytic Leukemia:

32
id Description HPO Frequency HPO Source Accession
1 juvenile myelomonocytic leukemia 32 HP:0012209

UMLS symptoms related to Juvenile Myelomonocytic Leukemia:


exanthema, fatigue, fever

GenomeRNAi Phenotypes related to Juvenile Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.11 KRAS
2 Decreased viability GR00106-A-0 10.11 KRAS
3 Decreased viability GR00173-A 10.11 FLT3
4 Decreased viability GR00221-A-1 10.11 KRAS NF1 NRAS RAF1 FLT3
5 Decreased viability GR00221-A-2 10.11 KRAS NF1 RAF1
6 Decreased viability GR00221-A-3 10.11 NRAS
7 Decreased viability GR00221-A-4 10.11 NF1 FLT3
8 Decreased viability GR00231-A 10.11 RAF1
9 Decreased viability GR00301-A 10.11 RAF1 KRAS
10 Decreased viability GR00381-A-1 10.11 KRAS
11 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.94 SOS1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.94 BRAF
13 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.94 PTPN11
14 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.94 SOS1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.94 PTPN11
16 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.94 CBL
17 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.94 SOS1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.94 CBL SOS1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.94 PTPN11
20 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.94 NF1 PTPN11 BRAF RAF1 SOS1 CBL
21 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.94 CBL RAF1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.94 RAF1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.94 BRAF
24 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.94 BRAF
25 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.94 PTPN11
26 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.94 CBL
27 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.94 PTPN11
28 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.94 BRAF
29 Increased shRNA abundance (Z-score > 2) GR00366-A-201 9.94 CBL
30 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.94 CBL
31 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.94 BRAF
32 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.94 BRAF
33 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.94 BRAF
34 Increased shRNA abundance (Z-score > 2) GR00366-A-37 9.94 PTPN11
35 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.94 CBL
36 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.94 NF1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.94 PTPN11 BRAF
38 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.94 RAF1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.94 PTPN11
40 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.94 NF1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.94 PTPN11
42 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.94 CBL
43 Increased shRNA abundance (Z-score > 2) GR00366-A-97 9.94 NF1
44 Decreased cell migration GR00055-A-1 9.73 ARHGAP26 BRAF CBL KRAS NF1 SOS1
45 Increased cell migration GR00055-A-3 9.35 BRAF CBL KRAS NF1 SOS1

MGI Mouse Phenotypes related to Juvenile Myelomonocytic Leukemia:

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 CSF2 FLT3 KRAS NF1 NRAS PTPN11
2 hematopoietic system MP:0005397 10.39 CBL CSF2 FLT3 KRAS NF1 NRAS
3 cardiovascular system MP:0005385 10.36 BRAF CBL CSF2 KRAS NF1 NRAS
4 growth/size/body region MP:0005378 10.35 BRAF CBL CSF2 FLT3 KRAS NF1
5 immune system MP:0005387 10.35 TET2 BRAF CBL CSF2 FLT3 KRAS
6 homeostasis/metabolism MP:0005376 10.34 RAF1 RRAS RUNX1 SAMD9L SETBP1 SOS1
7 endocrine/exocrine gland MP:0005379 10.33 KRAS NF1 NRAS PTPN11 RAF1 RUNX1
8 craniofacial MP:0005382 10.27 BRAF CBL CSF2 KRAS NF1 NRAS
9 mortality/aging MP:0010768 10.25 KRAS NF1 NRAS PTPN11 RAF1 RUNX1
10 embryo MP:0005380 10.21 SOS1 BRAF CSF2 KRAS NF1 NRAS
11 integument MP:0010771 10.2 NRAS PTPN11 RAF1 RUNX1 SAMD9L SOS1
12 neoplasm MP:0002006 10.1 BRAF CSF2 FLT3 KRAS NF1 NRAS
13 liver/biliary system MP:0005370 10.09 BRAF CBL KRAS NF1 NRAS PTPN11
14 hearing/vestibular/ear MP:0005377 10 BRAF CBL KRAS NF1 PTPN11 RAF1
15 muscle MP:0005369 9.97 ARHGAP26 BRAF CBL KRAS NF1 PTPN11
16 no phenotypic analysis MP:0003012 9.86 FLT3 KRAS NRAS PTPN11 RAF1 RUNX1
17 pigmentation MP:0001186 9.63 BRAF CBL KRAS NF1 NRAS PTPN11
18 respiratory system MP:0005388 9.61 BRAF CBL CSF2 KRAS NF1 PTPN11
19 skeleton MP:0005390 9.32 BRAF CBL CSF2 FLT3 KRAS NF1

Drugs & Therapeutics for Juvenile Myelomonocytic Leukemia

Drugs for Juvenile Myelomonocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
3 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
4 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
6
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
7
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
8
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
9
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
10
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
11 Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
12
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
13
Asparaginase Approved Phase 3 9015-68-3
14
Daunorubicin Approved Phase 3 20830-81-3 30323
15
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
16
Thioguanine Approved Phase 3 154-42-7 2723601
17
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
18
Lorazepam Approved Phase 3 846-49-1 3958
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
21
Butyric Acid Experimental Phase 3 107-92-6 264
22 6-Mercaptopurine Phase 3
23 Anti-Infective Agents Phase 3,Phase 2,Phase 1
24 Antimetabolites Phase 3,Phase 2,Phase 1
25 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
26 Antiviral Agents Phase 3,Phase 2,Phase 1
27 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
28 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
29 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
30 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
31 Dermatologic Agents Phase 3,Phase 2,Phase 1
32 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
33 Vitamin B Complex Phase 3,Phase 2,Phase 1
34 Antibodies Phase 3,Phase 2
35 Cyclosporins Phase 3,Phase 2,Phase 1
36 Immunoglobulins Phase 3,Phase 2
37 Bone Density Conservation Agents Phase 3
38 Calcium, Dietary Phase 3
39 Muromonab-CD3 Phase 3,Phase 2
40 Cortisol succinate Phase 3
41 Hydrocortisone 17-butyrate 21-propionate Phase 3
42 Hydrocortisone acetate Phase 3
43 Hydrocortisone-17-butyrate Phase 3
44 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
45 Acyclovir Phase 3
46 valacyclovir Phase 3
47 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
48 Etoposide phosphate Phase 3,Phase 2,Phase 1
49 Adjuvants, Immunologic Phase 3,Phase 1,Phase 2
50 Folate Nutraceutical Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 113)

id Name Status NCT ID Phase Drugs
1 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4 Busulfan/Cyclophosphamide
2 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
3 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
4 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
5 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
6 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
7 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
8 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
9 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
10 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
11 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
12 Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Recruiting NCT00619879 Phase 3 Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients;Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies
13 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases Terminated NCT00450450 Phase 3
14 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
15 Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
16 Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia Completed NCT00025038 Phase 2 tipifarnib;isotretinoin;fludarabine phosphate;cytarabine;cyclophosphamide
17 A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies Completed NCT01036009 Phase 2
18 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
19 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
20 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
21 Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies Completed NCT00143559 Phase 2 Systematic chemotherapy and antibodies
22 Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Completed NCT00309907 Phase 2 methylprednisolone
23 Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies Completed NCT00145613 Phase 2 Systemic chemotherapy and antibodies
24 T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia Completed NCT00002718 Phase 2 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
25 Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer Completed NCT00126477 Phase 2
26 Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease Completed NCT00003913 Phase 2 busulfan;cyclophosphamide;methylprednisolone
27 Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00054327 Phase 2 busulfan;cyclophosphamide;cytarabine;Etoposide
28 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer Completed NCT00014469 Phase 2 busulfan;melphalan;methotrexate;tacrolimus
29 Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
30 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
31 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
32 Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
33 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
34 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
35 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2 methylprednisolone;prednisone
36 Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease Completed NCT00118326 Phase 1, Phase 2
37 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
38 Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) Recruiting NCT02447666 Phase 2 Azacitidine
39 Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) Recruiting NCT00167219 Phase 1, Phase 2 Preparative Regimen
40 Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Recruiting NCT03190915 Phase 2 Trametinib
41 CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant Recruiting NCT02061800 Phase 1, Phase 2 Thiotepa;Cyclophosphamide;Alemtuzumab;Tacrolimus;Melphalan;Busulfan;Fludarabine;Methylprednisolone
42 Phase II Trial of Myeloablative Conditioning & Transplantation of Partially HLA-mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies Recruiting NCT02120157 Phase 2 Cyclophosphamide;Busulfan;Tacrolimus;Mycophenolate mofetil
43 Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine Recruiting NCT02996773 Phase 1, Phase 2 Bendamustine;Cyclophosphamide
44 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
45 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
46 Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting NCT02790515 Phase 2 Anti-thymocyte globulin (rabbit);Blinatumomab;Cyclophosphamide;Fludarabine;G-CSF;Melphalan;Mesna;Rituximab;Tacrolimus;Thiotepa;Sirolimus
47 Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases Recruiting NCT00309842 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
48 Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia Active, not recruiting NCT01824693 Phase 2 Busulfan;Cyclophosphamide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
49 Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation Active, not recruiting NCT02458235 Phase 2 azacitidine
50 Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies Active, not recruiting NCT02333058 Phase 2 Treosulfan

Search NIH Clinical Center for Juvenile Myelomonocytic Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Juvenile Myelomonocytic Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Juvenile Myelomonocytic Leukemia:
Hemacord
Embryonic/Adult Cultured Cells Related to Juvenile Myelomonocytic Leukemia:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD PMIDs: 9828244

Cochrane evidence based reviews: leukemia, myelomonocytic, juvenile

Genetic Tests for Juvenile Myelomonocytic Leukemia

Genetic tests related to Juvenile Myelomonocytic Leukemia:

id Genetic test Affiliating Genes
1 Juvenile Myelomonocytic Leukemia 29

Anatomical Context for Juvenile Myelomonocytic Leukemia

MalaCards organs/tissues related to Juvenile Myelomonocytic Leukemia:

39
Bone, Bone Marrow, Myeloid, T Cells, Lymph Node, Kidney, Nk Cells

Publications for Juvenile Myelomonocytic Leukemia

Articles related to Juvenile Myelomonocytic Leukemia:

(show top 50) (show all 244)
id Title Authors Year
1
Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome. ( 28098151 )
2017
2
Juvenile myelomonocytic leukemia with prominent CD141 myeloid dendritic cell differentiation. ( 28414089 )
2017
3
Juvenile myelomonocytic leukemia in an infant with congenital human immunodeficiency virus and cytomegalovirus infection. ( 28612348 )
2017
4
Transient juvenile myelomonocytic leukemia in the setting of PTPN11 mutation and Noonan syndrome with secondary development of monosomy 7. ( 28084675 )
2017
5
Epigenetic dysregulation of the erythropoietic transcription factor KLF1 and the I^-like globin locus in juvenile myelomonocytic leukemia. ( 28749240 )
2017
6
Juvenile Myelomonocytic Leukemia: Profile and Outcome. ( 28755173 )
2017
7
Association Between Juvenile Myelomonocytic Leukemia, Juvenile Xanthogranulomas and Neurofibromatosis Type 1: Case Report and Review of the Literature. ( 28111791 )
2017
8
Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia. ( 27748021 )
2017
9
Diagnostic considerations in juvenile myelomonocytic leukemia in tropical settings. ( 28263030 )
2017
10
Blastic transformation of juvenile myelomonocytic leukemia caused by the copy number gain of oncogenic KRAS. ( 28244637 )
2017
11
Juvenile myelomonocytic leukemia presenting as bilateral breast masses. ( 27717995 )
2017
12
Juvenile Myelomonocytic Leukemia in Turkey: A Retrospective Analysis of 65 Patients. ( 28179213 )
2017
13
Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia. ( 26983639 )
2016
14
CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia. ( 27158276 )
2016
15
Early T-Cell Precursor Acute Lymphoblastic Leukemia in an Infant With an NRAS Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia. ( 27145535 )
2016
16
Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia. ( 26891149 )
2016
17
Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia. ( 26757980 )
2016
18
Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bone marrow transplantation or cell therapy (SFGM-TC). ( 27184944 )
2016
19
Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group. ( 26980750 )
2016
20
LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia. ( 26712910 )
2016
21
MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. ( 27447965 )
2016
22
Molluscum Mimicker: Juvenile Xanthogranulomas with Associated Juvenile Myelomonocytic Leukemia. ( 27514241 )
2016
23
Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy. ( 26911351 )
2016
24
Diagnosis and treatment of juvenile myelomonocytic leukemia. ( 27322988 )
2016
25
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group. ( 25704135 )
2015
26
Neutrophilic figurate erythema of infancy associated with juvenile myelomonocytic leukemia. ( 25623543 )
2015
27
Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. ( 25552679 )
2015
28
Neurofibromatosis type 1 diagnosed in a child based on multiple juvenile xanthogranulomas and juvenile myelomonocytic leukemia. ( 25516272 )
2015
29
Juvenile myelomonocytic leukemia. ( 25435114 )
2015
30
Nonsyndromic Juvenile Myelomonocytic Leukemia With PTPN11 Mutation in a 9-Year-old Girl. ( 26181421 )
2015
31
Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. ( 26457648 )
2015
32
How I treat juvenile myelomonocytic leukemia. ( 25564399 )
2015
33
Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. ( 25838281 )
2015
34
Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan. ( 25504334 )
2015
35
Generalized lichen nitidus associated with neurofibromatosis type 1 and juvenile myelomonocytic leukemia. ( 26341890 )
2015
36
Juvenile myelomonocytic leukemia due to a germline CBL Y371C mutation: 35-year follow-up of a large family. ( 25939664 )
2015
37
Lineage-dependent skewing of loss of heterozygosity (LOH) of KRAS gene in a case of juvenile myelomonocytic leukemia. ( 24766281 )
2014
38
RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia. ( 25147919 )
2014
39
Stem cell transplant for juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. ( 25332531 )
2014
40
Aggressive congenital juvenile myelomonocytic leukemia associated with somatic KRAS p.G13D mutation and concurrent germline IGF1R duplication. ( 25110823 )
2014
41
Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia. ( 24496301 )
2014
42
Concurrent juvenile myelomonocytic leukemia and T-lymphoblastic lymphoma with a shared missense mutation in NRAS. ( 24610751 )
2014
43
Control of thrombotic thrombocytopenic purpura by sirolimus in a child with juvenile myelomonocytic leukemia and somatic N-RAS mutation. ( 24590757 )
2014
44
Germline mutation of CBL is associated with moyamoya disease in a child with juvenile myelomonocytic leukemia and Noonan syndrome-like disorder. ( 25283271 )
2014
45
Successful second unrelated cord blood transplantation in a child with juvenile myelomonocytic leukemia. ( 24978300 )
2014
46
Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. ( 25395418 )
2014
47
Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. ( 25163700 )
2014
48
Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation. ( 24734223 )
2014
49
Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. ( 24578498 )
2014
50
Osteopetrosis mimicking juvenile myelomonocytic leukemia. ( 25335998 )
2014

Variations for Juvenile Myelomonocytic Leukemia

UniProtKB/Swiss-Prot genetic disease variations for Juvenile Myelomonocytic Leukemia:

71 (show all 18)
id Symbol AA change Variation ID SNP ID
1 ARHGAP26 p.Asn417Ser VAR_013623 rs121918546
2 KRAS p.Gly12Asp VAR_016026 rs121913529
3 KRAS p.Gly12Ser VAR_016028 rs121913530
4 KRAS p.Gly13Asp VAR_016029 rs112445441
5 NRAS p.Gly13Asp VAR_063084 rs121434596
6 NRAS p.Gly12Asp VAR_071129 rs121913237
7 PTPN11 p.Asp61Val VAR_015991 rs121918461
8 PTPN11 p.Asp61Tyr VAR_015992
9 PTPN11 p.Glu69Lys VAR_015993
10 PTPN11 p.Ala72Thr VAR_015996 rs121918453
11 PTPN11 p.Ala72Val VAR_015997 rs121918454
12 PTPN11 p.Glu76Ala VAR_015998 rs121918465
13 PTPN11 p.Glu76Gly VAR_015999 rs121918465
14 PTPN11 p.Glu76Lys VAR_016000 rs121918464
15 PTPN11 p.Glu76Val VAR_016001 rs121918465
16 PTPN11 p.Gly507Ala VAR_016002 rs397507546
17 PTPN11 p.Gly507Arg VAR_016003 rs397507545
18 SETBP1 p.Asp868Asn VAR_063807 rs267607042

ClinVar genetic disease variations for Juvenile Myelomonocytic Leukemia:

6 (show all 19)
id Gene Variation Type Significance SNP ID Assembly Location
1 NF1 NM_000267.3(NF1): c.4614G> A (p.Trp1538Ter) single nucleotide variant Pathogenic rs137854555 GRCh37 Chromosome 17, 29588828: 29588828
2 NF1 NF1, IVS34, G-A, +18 single nucleotide variant Pathogenic
3 NF1 NM_000267.3(NF1): c.1642-8A> G single nucleotide variant Pathogenic rs267606602 GRCh37 Chromosome 17, 29548860: 29548860
4 ARHGAP26 NM_015071.5(ARHGAP26): c.1250A> G (p.Asn417Ser) single nucleotide variant Pathogenic rs121918546 GRCh37 Chromosome 5, 142421420: 142421420
5 ARHGAP26 ARHGAP26, 52-BP INS insertion Pathogenic
6 ARHGAP26 ARHGAP26, 74-BP INS insertion Pathogenic
7 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
8 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
9 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
10 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
11 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
12 PTPN11 NM_002834.4(PTPN11): c.227A> T (p.Glu76Val) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
13 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
14 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
15 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
16 CBL NM_005188.3(CBL): c.1112A> G (p.Tyr371Cys) single nucleotide variant Pathogenic rs387906666 GRCh37 Chromosome 11, 119148892: 119148892
17 NRAS NM_002524.4(NRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
18 CBL NM_005188.3(CBL): c.1228-2A> G single nucleotide variant Pathogenic/Likely pathogenic rs727504426 GRCh37 Chromosome 11, 119149218: 119149218
19 PTPN11 NM_002834.4(PTPN11): c.181G> T (p.Asp61Tyr) single nucleotide variant Pathogenic rs397507510 GRCh38 Chromosome 12, 112450361: 112450361

Expression for Juvenile Myelomonocytic Leukemia

Search GEO for disease gene expression data for Juvenile Myelomonocytic Leukemia.

Pathways for Juvenile Myelomonocytic Leukemia

Pathways related to Juvenile Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 118)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 BRAF CBL CSF2 FLT3 KRAS NF1
2
Show member pathways
13.65 BRAF CBL FLT3 KRAS NRAS PTPN11
3
Show member pathways
13.6 BRAF CSF2 KRAS NF1 NRAS PTPN11
4
Show member pathways
13.43 BRAF CBL CSF2 FLT3 KRAS NF1
5
Show member pathways
13.39 BRAF CBL FLT3 KRAS NRAS RAF1
6
Show member pathways
13.31 BRAF CBL KRAS NRAS RAF1 RRAS
7
Show member pathways
13.15 BRAF KRAS NRAS RAF1 RRAS SOS1
8
Show member pathways
13.11 BRAF CBL KRAS NRAS RAF1 RRAS
9
Show member pathways
13.02 BRAF CBL KRAS NRAS PTPN11 RAF1
10
Show member pathways
13.01 BRAF KRAS NRAS RAF1 RRAS SOS1
11
Show member pathways
13 BRAF KRAS NRAS RAF1 RRAS SOS1
12
Show member pathways
12.99 BRAF KRAS NRAS RAF1 RRAS SOS1
13
Show member pathways
12.98 BRAF KRAS NRAS RAF1 RRAS SOS1
14
Show member pathways
12.98 BRAF CBL KRAS NRAS RAF1 SOS1
15
Show member pathways
12.93 BRAF CBL KRAS NRAS RAF1 RRAS
16
Show member pathways
12.92 BRAF CBL KRAS NRAS PTPN11 RAF1
17
Show member pathways
12.91 BRAF KRAS NRAS RAF1 SPRED1
18
Show member pathways
12.9 BRAF CBL KRAS PTPN11 RAF1 SOS1
19
Show member pathways
12.86 CBL KRAS NRAS RAF1 SOS1
20
Show member pathways
12.83 BRAF KRAS NF1 NRAS PTPN11 RAF1
21
Show member pathways
12.82 CBL KRAS NRAS PTPN11 SOS1
22 12.81 BRAF KRAS NF1 NRAS RAF1 RRAS
23
Show member pathways
12.79 BRAF KRAS NRAS RAF1 RRAS SOS1
24
Show member pathways
12.77 BRAF KRAS NRAS RAF1 RRAS
25 12.75 BRAF KRAS NRAS RAF1 RRAS SOS1
26 12.71 BRAF CBL FLT3 KRAS NRAS RAF1
27
Show member pathways
12.7 CBL CSF2 KRAS NRAS PTPN11 RAF1
28
Show member pathways
12.68 BRAF CBL KRAS NRAS PTPN11 SOS1
29
Show member pathways
12.62 BRAF KRAS NRAS RAF1 SOS1
30
Show member pathways
12.61 CBL KRAS NRAS PTPN11 RAF1 SOS1
31
Show member pathways
12.6 BRAF CBL CSF2 FLT3 KRAS NF1
32
Show member pathways
12.58 BRAF CBL KRAS NRAS RAF1 RRAS
33
Show member pathways
12.54 BRAF CBL KRAS NRAS RAF1 RRAS
34
Show member pathways
12.53 BRAF KRAS NRAS RAF1 RRAS SOS1
35
Show member pathways
12.52 KRAS NRAS PTPN11 RAF1 RRAS SOS1
36
Show member pathways
12.51 BRAF KRAS NF1 PTPN11 RAF1 SOS1
37
Show member pathways
12.51 BRAF CBL CSF2 KRAS NRAS PTPN11
38 12.5 CSF2 KRAS NRAS RRAS
39
Show member pathways
12.49 KRAS NRAS RAF1 RRAS SOS1
40
Show member pathways
12.48 CBL KRAS NRAS PTPN11 SOS1
41
Show member pathways
12.47 CBL PTPN11 RAF1 SOS1
42
Show member pathways
12.47 CBL RAF1 RRAS SOS1
43
Show member pathways
12.45 CBL KRAS NRAS PTPN11 RAF1
44
Show member pathways
12.44 BRAF CBL KRAS NRAS PTPN11 RAF1
45
Show member pathways
12.43 BRAF KRAS NF1 NRAS RAF1
46
Show member pathways
12.42 CBL FLT3 KRAS NRAS PTPN11 RAF1
47
Show member pathways
12.35 BRAF CBL KRAS NRAS RAF1 RRAS
48 12.34 KRAS NRAS PTPN11 RAF1 RRAS
49
Show member pathways
12.34 CBL CSF2 KRAS NRAS PTPN11 RAF1
50
Show member pathways
12.33 KRAS NRAS PTPN11 SOS1

GO Terms for Juvenile Myelomonocytic Leukemia

Biological processes related to Juvenile Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.8 KRAS NRAS PTPN11 SOS1
2 axon guidance GO:0007411 9.78 KRAS NRAS PTPN11 SOS1
3 fibroblast growth factor receptor signaling pathway GO:0008543 9.69 CBL PTPN11 SPRED1
4 visual learning GO:0008542 9.58 BRAF KRAS NF1
5 MAPK cascade GO:0000165 9.56 BRAF CSF2 KRAS NF1 NRAS RAF1
6 epidermal growth factor receptor signaling pathway GO:0007173 9.55 CBL KRAS NRAS PTPN11 SOS1
7 regulation of synaptic transmission, GABAergic GO:0032228 9.54 KRAS NF1
8 ERBB2 signaling pathway GO:0038128 9.54 KRAS NRAS SOS1
9 dendritic cell differentiation GO:0097028 9.52 CSF2 FLT3
10 myeloid progenitor cell differentiation GO:0002318 9.43 BRAF FLT3
11 neurotrophin TRK receptor signaling pathway GO:0048011 9.43 PTPN11 RAF1 SOS1
12 forebrain astrocyte development GO:0021897 9.32 KRAS NF1
13 Ras protein signal transduction GO:0007265 9.1 KRAS NF1 NRAS RIT1 RRAS SOS1
14 signal transduction GO:0007165 10.11 ARHGAP26 BRAF KRAS NF1 NRAS RAF1

Molecular functions related to Juvenile Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.55 ARHGAP26 BRAF CBL CSF2 FLT3 KRAS
2 mitogen-activated protein kinase kinase binding GO:0031434 9.26 BRAF RAF1
3 protein complex binding GO:0032403 9.26 FLT3 KRAS NRAS RRAS
4 protein tyrosine kinase binding GO:1990782 9.16 CBL PTPN11

Sources for Juvenile Myelomonocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....